Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
21
04
2022
accepted:
30
08
2022
medline:
21
8
2023
pubmed:
10
9
2022
entrez:
9
9
2022
Statut:
ppublish
Résumé
The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed. A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial was conducted to assess the efficacy of daily NRPT (commercially known as Basis, a combination of nicotinamide riboside and pterostilbene) supplementation in 111 adults with NAFLD. The study consisted of three arms: placebo, recommended daily dose of NRPT (NRPT 1×), and a double dose of NRPT (NRPT 2×). NRPT appeared safe and well tolerated. At the end of the study, no significant change was seen in the primary endpoint of hepatic fat fraction with respect to placebo. However, among prespecified secondary outcomes, a time-dependent decrease in the circulating levels of the liver enzymes alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) was observed in the NRPT 1× group, and this decrease was significant with respect to placebo. Furthermore, a significant decrease in the circulating levels of the toxic lipid ceramide 14:0 was also observed in the NRPT 1× group versus placebo, and this decrease was associated with a decrease in ALT in individuals of this group. A dose-dependent effect was not observed with respect to ALT, GGT, or ceramide 14:0 in the NRPT 2× group. This study demonstrates that NRPT at the recommended dose is safe and may hold promise in lowering markers of hepatic inflammation in patients with NAFLD.
Sections du résumé
BACKGROUND AND AIMS
The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
APPROACH AND RESULTS
A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial was conducted to assess the efficacy of daily NRPT (commercially known as Basis, a combination of nicotinamide riboside and pterostilbene) supplementation in 111 adults with NAFLD. The study consisted of three arms: placebo, recommended daily dose of NRPT (NRPT 1×), and a double dose of NRPT (NRPT 2×). NRPT appeared safe and well tolerated. At the end of the study, no significant change was seen in the primary endpoint of hepatic fat fraction with respect to placebo. However, among prespecified secondary outcomes, a time-dependent decrease in the circulating levels of the liver enzymes alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) was observed in the NRPT 1× group, and this decrease was significant with respect to placebo. Furthermore, a significant decrease in the circulating levels of the toxic lipid ceramide 14:0 was also observed in the NRPT 1× group versus placebo, and this decrease was associated with a decrease in ALT in individuals of this group. A dose-dependent effect was not observed with respect to ALT, GGT, or ceramide 14:0 in the NRPT 2× group.
CONCLUSIONS
This study demonstrates that NRPT at the recommended dose is safe and may hold promise in lowering markers of hepatic inflammation in patients with NAFLD.
Identifiants
pubmed: 36082508
pii: 01515467-202309000-00018
doi: 10.1002/hep.32778
doi:
Substances chimiques
pterostilbene
26R60S6A5I
nicotinamide-beta-riboside
0I8H2M0L7N
gamma-Glutamyltransferase
EC 2.3.2.2
Alanine Transaminase
EC 2.6.1.2
Banques de données
ClinicalTrials.gov
['NCT03513523']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
863-877Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Pais R, Maurel T. Natural history of NAFLD. J Clin Med. 2021;10:1161.
Dall M, Hassing AS, Treebak JT. NAD + and NAFLD—caution, causality and careful optimism. J Physiol. 2022;600:1135–54.
Poss AM, Summers SA. Too much of a good thing? An evolutionary theory to explain the role of ceramides in NAFLD. Front Endocrinol (Lausanne). 2020;11:505.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57.
Apostolopoulou M, Gordillo R, Koliaki C, Gancheva S, Jelenik T, De Filippo E, et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diabetes Care. 2018;41:1235–43.
Imai S, Guarente L. NAD + and sirtuins in aging and disease. Trends Cell Biol. 2014;24:464–71.
Picard F, Kurtev M, Chung N, Topark‐Ngarm A, Senawong T, Machado De Oliveira R, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR‐gamma. Nature. 2004;429:771–6.
Lagouge M, Argmann C, Gerhart‐Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC‐1alpha. Cell. 2006;127:1109–22.
Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell. 2011;44:177–90.
Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature. 2006;444:868–74.
Li Y, Xu S, Giles A, Nakamura K, Lee JW, Hou X, et al. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J. 2011;25:1664–79.
Li Y, Wong K, Giles A, Jiang J, Lee JW, Adams AC, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology. 2014;146:539–49.e7.
Ding RB, Bao J, Deng CX. Emerging roles of SIRT1 in fatty liver diseases. Int J Biol Sci. 2017;13:852–67.
He W, Wang Y, Zhang MZ, You L, Davis LS, Fan H, et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest. 2010;120:1056–68.
Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, et al. The NAD + precursor nicotinamide riboside enhances oxidative metabolism and protects against high‐fat diet–induced obesity. Cell Metab. 2012;15:838–47.
Gariani K, Menzies KJ, Ryu D, Wegner CJ, Wang X, Ropelle ER, et al. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology. 2016;63:1190–204.
Hubbard BP, Sinclair DA. Small molecule SIRT1 activators for the treatment of aging and age‐related diseases. Trends Pharmacol Sci. 2014;35:146–54.
Cheng Y, Di S, Fan C, Cai L, Gao C, Jiang P, et al. SIRT1 activation by pterostilbene attenuates the skeletal muscle oxidative stress injury and mitochondrial dysfunction induced by ischemia reperfusion injury. Apoptosis. 2016;21:905–16.
Guo Y, Zhang L, Li F, Hu CP, Zhang Z. Restoration of sirt1 function by pterostilbene attenuates hypoxia‐reoxygenation injury in cardiomyocytes. Eur J Pharmacol. 2016;776:26–33.
Liu Y, You Y, Lu J, Chen X, Yang Z. Recent advances in synthesis, bioactivity, and pharmacokinetics of pterostilbene, an important analog of resveratrol. Molecules. 2020;25:5166.
Aguirre L, Palacios‐Ortega S, Fernandez‐Quintela A, Hijona E, Bujanda L, Portillo MP. Pterostilbene reduces liver steatosis and modifies hepatic fatty acid profile in obese rats. Nutrients. 2019;11:961.
Obrador E, Salvador R, Marchio P, Lopez‐Blanch R, Jihad‐Jebbar A, Rivera P, et al. Nicotinamide riboside and pterostilbene cooperatively delay motor neuron failure in ALS SOD1(G93A) Mice. Mol Neurobiol. 2021;58:1345–71.
Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double‐blind, placebo‐controlled study. NPJ Aging Mech Dis. 2017;3:17.
Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, Wolfson T, et al. Nonalcoholic fatty liver disease: diagnostic and fat‐grading accuracy of low‐flip‐angle multiecho gradient‐recalled‐echo MR imaging at 1.5 T. Radiology. 2009;251:67–76.
Mashhood A, Railkar R, Yokoo T, Levin Y, Clark L, Fox‐Bosetti S, et al. Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. J Magn Reson Imaging. 2013;37:1359–70.
Yokoo T, Shiehmorteza M, Hamilton G, Wolfson T, Schroeder ME, Middleton MS, et al. Estimation of hepatic proton‐density fat fraction by using MR imaging at 3.0 T. Radiology. 2011;258:749–59.
Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. A randomized placebo‐controlled clinical trial of nicotinamide riboside in obese men: safety, insulin‐sensitivity, and lipid‐mobilizing effects. Am J Clin Nutr. 2018;108:343–53.
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
Hajduch E, Lachkar F, Ferre P, Foufelle F. Roles of ceramides in non‐alcoholic fatty liver disease. J Clin Med. 2021;10:792.
Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. Gastroenterology. 2019;156:88–95.e5.
Gomez‐Zorita S, Gonzalez‐Arceo M, Trepiana J, Aguirre L, Crujeiras AB, Irles E, et al. Comparative effects of pterostilbene and its parent compound resveratrol on oxidative stress and inflammation in steatohepatitis induced by high‐fat high‐fructose feeding. Antioxidants (Basel). 2020;9:1042.
Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol. 2021;18:701–11.
Poss AM, Maschek JA, Cox JE, Hauner BJ, Hopkins PN, Hunt SC, et al. Machine learning reveals serum sphingolipids as cholesterol‐independent biomarkers of coronary artery disease. J Clin Invest. 2020;130:1363–76.
Maldonado‐Hernandez J, Saldana‐Davila GE, Pina‐Aguero MI, Nunez‐Garcia BA, Lopez‐Alarcon MG. Association between plasmatic ceramides profile and AST/ALT ratio: C14:0 ceramide as predictor of hepatic steatosis in adolescents independently of obesity. Can J Gastroenterol Hepatol. 2017;2017:3689375.